KRAS is the most frequently mutated oncogene in human cancer, yet no therapies are
available to treat KRAS mutant cancers. We used two independent reverse genetic …

Targeting KRAS mutant tumors through inhibition of individual downstream pathways has
had limited clinical success. Here we report that RAF inhibitors exhibit little efficacy in KRAS …

The mutation of K‐RAS represents one of the most frequent genetic alterations in cancer.
Targeting of downstream effectors of RAS, including of MEK and ERK, has limited clinical …

Mitogen-activated protein kinase (MAPK) pathway dysregulation is implicated in> 30% of all
cancers, rationalizing the development of RAF, MEK and ERK inhibitors. While BRAF and …

KRAS genes are the most commonly mutated oncogenes in cancer. Unfortunately, effective
therapeutic strategies for targeting KRAS mutant cancers have proven to be difficult to …

There are no effective therapies for the∼ 30% of human malignancies with mutant RAS
oncogenes. Using a kinome-centered synthetic lethality screen, we find that suppression of …

Aberrations in rat sarcoma (RAS) viral oncogene are the most prevalent and best-known
genetic alterations identified in human cancers. Indeed, RAS drives tumorigenesis as one of …

KRAS mutations occur in a quarter of all of human cancers, yet no selective drug has been
approved to treat these tumors. Despite the recent development of drugs that block KRAS …

Abstract The RAS-RAF-MEK1/2-ERK1/2 pathway is a key signal transduction pathway in the
cells. Critically, it remains constitutively active in approximately 30% of human cancers …

Abstract The RAS/RAF/MEK pathway is activated in more than 30% of human cancers, most
commonly via mutation in the K-ras oncogene and also via mutations in BRAF. Several …